Previous close | 6.25 |
Open | 5.95 |
Bid | 5.84 x 100 |
Ask | 5.91 x 200 |
Day's range | 5.44 - 6.18 |
52-week range | 2.09 - 8.17 |
Volume | |
Avg. volume | 201,931 |
Market cap | 151.879M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 6.87 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Syros Pharmaceuticals ( NASDAQ:SYRS ) Full Year 2023 Results Key Financial Results Net loss: US$164.6m (loss widened by...
These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors can...
Syros (SYRS) is progressing well with the development of its pipeline candidate, tamibarotene, targeting two different cancer indications.